Blood tacrolimus concentrations in bone marrow transplant patients undergoing plasmapheresis

Bone Marrow Transplantation

Volumn 25, Issue 4, 2000, Pages 449-451

  Hale, G A ^a,b   Reece, D E ^a   Munn, R K ^a   Kniska, A B ^a   Phillips, G L ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

BMT; GVHD; Microangiopathic hemolytic anemia; Pharmacokinetics; Plasmapheresis; Tacrolimus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INFANT; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0034004191     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702174     Document Type: Article

References (16)

1. Tzakis AG, Abu-Elmagd K, Fung JJ et al. FK506 rescue in chronic graft-versus-host disease after bone marrow transplantation. Transplant Proc 1991; 23: 3225-3227.
2. Koehler MT, Howrie D, Mirro J et al. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing hone marrow transplantation. Bone Marrow Transplant 1995; 15: 895-899.
3. Nash R, Etzionir, Storb R et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single center study. Blood 1995; 85: 3746-3753.
4. Wingard JR, Nash RA, Przepiorka D et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after JHLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant 1998; 4: 157-163.
5. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994; 14: 495-504.
6. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
7. Marciniak E, Bailey K, Henslee-Downey PJ. Thompson JS. Bone marrow purging of T lymphocytes with T10B9 monoclonal antibody and complement. In: EM Areman (ed). Bone Marrow and Stem Cell Processing: A Manual of Current Techniques. FA Davis: Philadelphia, 1992, pp 208-210.
8. Venkataramanan R. Swaminathan A, Prasad T et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404-430.
9. Jusko WJ. Piekoszewski W, Klintmalm GB et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281-290.
10. Mekki Q, Lee C, Aweeka F et al. Pharmacokinetics of tacrolimus (FK506) in kidney transplant patients. Clin Pharmacol Ther 1995; 53: 238 (Abstr.).
11. Boswell GW, Bekersky I, Fay J et al. Tacrolimus pharmacokinetics in BMT patients. Bone Marrow Transplant 1998; 21: 23-28.
12. Kershner RP, Fitzsimmons WE. Relationship of EK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920-926.
13. Winkler M, Ringe B, Baumann J et al. Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK506 for immunosuppression. Clin Chem 1994; 40: 2247-2253.
14. McMaster P, Mirza DI, Ismail T et al. Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit 1995; 17: 602-605.
15. Przepiorka D, Suzuki J, Ippoliti C et al. Blood tacrolimus concentration unchanged by plasmapheresis. Am J Hosp Pharm 1994; 51: 1708.
16. Jusko WJ, D'Ambrosio R. Monitoring tacrolimus concentrations in plasma and whole blood. Trans Proc 1991; 23: 2732-2735.